Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509819 | 0.93 | STAT3 (0.61) | STAT3HSP90AA1HSP90AB1MEN1MAPT | |
| SCHEMBL13509822 | 0.91 | STAT3 (0.59) | STAT3HSP90AA1HSP90AB1 | |
| SCHEMBL13509803 | 0.89 | STAT3 (0.67) | STAT3HSP90AA1HSP90AB1MEN1MAPT | |
| SCHEMBL13509820 | 0.88 | STAT3 (0.59) | STAT3HSP90AA1HSP90AB1 | |
| SCHEMBL13509816 | 0.86 | STAT3 (0.65) | STAT3HSP90AA1HSP90AB1MEN1MAPT | |
| SCHEMBL13509861 | 0.85 | STAT3 (0.64) | STAT3HSP90AA1HSP90AB1MEN1MAPT | |
| SCHEMBL13509795 | 0.84 | STAT3 (0.74) | STAT3HSP90AA1HSP90AB1MEN1MAPT | |
| SCHEMBL13509898 | 0.84 | STAT3 (0.55) | STAT3HSP90AA1HSP90AB1KMT2A | |
| SCHEMBL13509880 | 0.83 | STAT3 (0.53) | STAT3HSP90AA1HSP90AB1 | |
| SCHEMBL13509876 | 0.83 | STAT3 (0.72) | STAT3HSP90AA1HSP90AB1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021113551-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | BAYLOR COLLEGE OF MEDICINE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| WO-2009149192-A1 | STAT3 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | STAT3, MMP1, MMP8 | STAT3 1/4885HSP90AA1 347/4885HSP90AB1 230/4885 |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885HSP90AA1 231/4885HSP90AB1 254/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | STAT3 3/4885HSP90AA1 508/4885HSP90AB1 346/4885 |
| US-20140296270-A1 | STAT3 Inhibitors | STAT3, STAT1, JAK2 | STAT3 1/4885HSP90AA1 231/4885HSP90AB1 254/4885 |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | JAK2, STAT3, STAT6 | STAT3 2/4885HSP90AA1 1192/4885HSP90AB1 937/4885 |
| US-20110312984-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885HSP90AA1 231/4885HSP90AB1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.